EndoScreener

K211326 · Chengdu Wision Medical Device Co., Ltd. · QNP · Nov 19, 2021 · Gastroenterology, Urology

Device Facts

• Record ID: K211326
• Device Name: EndoScreener
• Applicant: Chengdu Wision Medical Device Co., Ltd.
• Product Code: QNP · Gastroenterology, Urology
• Decision Date: Nov 19, 2021
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 876.1520
• Device Class: Class 2
• Attributes: AI/ML, Software as a Medical Device

AI Performance

Output	Algorithm	Acceptance	Observed	Dev DS	Dev Readers	Test DS	Test Readers
Colorectal polyp detection	Customized deep learning model	—	—	1,138 consecutive polyp patients with histology confirmation	—	Multi-center, tandem colonoscopy, randomized controlled trial at four United States academic medical centers including 223 patients	—

Indications for Use

EndoScreener is intended as a stand-alone software for real-time automatic detection of polyps in colonoscopy video stream during the procedure. Physicians are responsible for reviewing the identified areas of suspect polyps presented by EndoScreener and confirming the presence or absence of a polyp on the evaluation of the colonoscopy image on their own medical judgment. EndoScreener is not intended to replace a full patient evaluation, nor is it intended to be relied upon to make or confirm a diagnosis.

Device Story

EndoScreener is a computer-aided detection (CADe) software for real-time polyp identification during colonoscopy. It ingests live colonoscopy video streams; processes frames using a deep learning algorithm to detect potential polyps; and outputs visual indicators (blue bounding boxes) overlaid on the monitor. It may also provide audible alerts. Used in clinical settings by endoscopists, the device serves as an adjunct to standard visual inspection. Physicians must review and confirm all detections based on their own medical judgment; the device does not replace clinical evaluation or confirm diagnoses. By highlighting suspicious lesions, it aims to assist clinicians in identifying polyps, potentially reducing adenoma miss rates.

Clinical Evidence

Clinical evidence includes a multi-center, tandem colonoscopy, randomized controlled trial at four U.S. academic medical centers (n=223 patients). The study compared CADe-assisted colonoscopy to routine colonoscopy. Primary endpoints included adenoma miss rate (AMR) and adenoma per colonoscopy (APC); results showed significantly lower AMR and higher APC in the CADe-first group. Nonclinical validation included testing on a dataset of 1,138 polyp patients with histology confirmation, evaluating per-image sensitivity/specificity, per-polyp sensitivity, and AUC. Bench testing confirmed no imaging degradation and negligible latency.

Technological Characteristics

Software-based CADe system; utilizes a deep learning model for real-time image analysis. Inputs: colonoscopy video stream. Outputs: visual bounding box overlays and optional audible alerts. Operates in real-time. Designed for integration with existing endoscopy hardware.

Indications for Use

Indicated for use by licensed endoscopists performing white light colonoscopy in adults for real-time automatic detection of polyps.

Regulatory Classification

Identification

A gastrointestinal lesion software detection system is a computer-assisted detection device used in conjunction with endoscopy for the detection of abnormal lesions in the gastrointestinal tract. This device with advanced software algorithms brings attention to images to aid in the detection of lesions. The device may contain hardware to support interfacing with an endoscope.

Special Controls

In combination with the general controls of the FD&C Act, the gastrointestinal lesion software detection system is subject to the following special controls:

*Classification.* Class II (special controls). The special controls for this device are:(1) Clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including detection of gastrointestinal lesions and evaluation of all adverse events. (2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Testing must include: (i) Standalone algorithm performance testing; (ii) Pixel-level comparison of degradation of image quality due to the device; (iii) Assessment of video delay due to marker annotation; and (iv) Assessment of real-time endoscopic video delay due to the device. (3) Usability assessment must demonstrate that the intended user(s) can safely and correctly use the device. (4) Performance data must demonstrate electromagnetic compatibility and electrical safety, mechanical safety, and thermal safety testing for any hardware components of the device. (5) Software verification, validation, and hazard analysis must be provided. Software description must include a detailed, technical description including the impact of any software and hardware on the device's functions, the associated capabilities and limitations of each part, the associated inputs and outputs, mapping of the software architecture, and a description of the video signal pipeline. (6) Labeling must include: (i) Instructions for use, including a detailed description of the device and compatibility information; (ii) Warnings to avoid overreliance on the device, that the device is not intended to be used for diagnosis or characterization of lesions, and that the device does not replace clinical decision making; (iii) A summary of the clinical performance testing conducted with the device, including detailed definitions of the study endpoints and statistical confidence intervals; and (iv) A summary of the standalone performance testing and associated statistical analysis.

Predicate Devices

• GI Genius (DEN 200055)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: a symbol on the left and the FDA name and title on the right. The symbol on the left is a stylized representation of a human figure, while the text on the right reads "FDA U.S. FOOD & DRUG ADMINISTRATION" in blue letters.

November 19, 2021

Chengdu Wision Medical Device Co., LTD. % John Smith Partner Hogan Lovells US LLP 555 Thirteenth St, NW Washington, DC 20004

Re: K211326

Trade/Device Name: EndoScreener Regulation Number: 21 CFR 876.1520 Regulation Name: Gastrointestinal lesion software detection system Regulatory Class: Class II Product Code: QNP Dated: November 18, 2021 Received: November 18, 2021

Dear John Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.

{1}------------------------------------------------

You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatoryinformation/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely,

Shanil P. Haugen, Ph.D. Assistant Director DHT3A: Division of Renal, Gastrointestinal, Obesity and Transplant Devices OHT3: Office of GastroRenal, ObGyn, General Hospital and Urology Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

510(k) Number (if known) K211326

Device Name

EndoScreener Indications for Use (Describe)

EndoScreener is intended as a stand-alone software for real-time automatic detection of polyps in colonoscopy video stream during the procedure.

Physicians are responsible for reviewing the identified areas of suspect polyps presented by EndoScreener and confirming the presence or absence of a polyp on the evaluation of the colonoscopy image on their own medical judgment. EndoScreener is not intended to replace a full patient evaluation, nor is it intended to be relied upon to make or confirm a diagnosis.

EndoScreener is indicated for use by licensed endoscopists who perform colonoscopy in adults. EndoScreener is indicated for use with white light colonoscopy.

Type of Use (Select one or both, as applicable)

区 Prescription Use (Part 21 CFR 801 Subpart D)

□ Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

# 510(k) SUMMARY

## Changdu Wision's EndoScreener

# Submitter

Chengdu Wision Medical Device Co., Ltd. Unit 802, Floor 8, Building 17, Yintaicheng No.1999 Yizhou Road, Wuhou District

Chengdu, Sichuan, China, 610041

Phone: [phone]

Contact Person: JingJia Liu

Date Prepared: November 16, 2021

Name of Device: EndoScreener

Common or Usual Name: Computer aided detection software for colorectal polyps

Classification Name: Gastrointestinal lesion software detection system

Requlatory Class: Class II (21 CFR 876.1520)

Product Code: QNP

Predicate Device: GI Genius (DEN 200055)

#### Device Description

The EndoScreener is a computer-assisted detection device for colorectal polyps. EndoScreener takes as input colonoscopy video stream from an endoscopy device, which is analyzed in real-time. The device output consists of blue boxes overlaid onto the colonoscopy images to highlight regions of potential polyp. EndoScreener also has the option to sound an alert to the physicians who perform the colonoscopy when a polyp has been detected. Following detection by EndoScreener, the physician must confirm the EndoScreener findings based on his/her own medical judgment.

#### Intended Use / Indications for Use

EndoScreener is intended as a stand-alone software for real-time automatic detection of polyps in colonoscopy video stream during the procedure.

Physicians are responsible for reviewing the identified areas of suspect polyps presented by EndoScreener and confirming the presence or absence of a polyp on the evaluation of the

{4}------------------------------------------------

colonoscopy image on the monitor and their own medical judgment. EndoScreener is not intended to replace a full patient evaluation, nor is it intended to be relied upon to make or confirm a diagnosis.

EndoScreener is indicated for use by licensed endoscopists who perform colonoscopy in adults. EndoScreener is indicated for use with white light colonoscopy.

### Summary of Technological Characteristics

At a high level, the subject and predicate devices are based on the following same technological elements:

- . Both the EndoScreener and the GI Genius use artificial intelligence algorithms to assist clinicians in detecting colon polyps colonoscopy examination.
- Both devices take as input a colonoscopy video stream from an endoscopy device and provide as an output a bounding box that highlights the detected polyps.
- Both devices are used in real-time to aid the clinicians in identifying abnormal lesions. .

The following technological differences exist between the subject and predicate devices:

- . The subject device uses a customized deep learning model, which is likely to be slightly different from the deep learning model and customization used by GI Genius.
### Performance Data

In the nonclinical testing of the subject device included validation of the deep learning algorithm on multiple datasets to evaluate per-image sensitivity and specificity as well as per-polyp sensitivity and AUC. Specifically, performance was evaluated on a dataset of 1,138 consecutive polyp patients with histology confirmation and acceptable performance was obtained. For all assessments performed, the EndoScreener functioned as intended and the polyp detection accuracy observed was as expected. Endoscopic imaging degradation and latency due to the device were also evaluated, with appropriate hardware components, and the software device produced no imaging degradation and ignorable end-to-end latency.

EndoScreener performance was also evaluated in a multi-center, tandem colonoscopy, randomized controlled trial, performed at four United States academic medical centers. The study included 223 patients with screening and surveillance indications, whom were randomized to CADe-routine group and Routine-CADe group for back-to-back colonoscopy procedures. The primary endpoint adenoma miss rate (AMR) was significantly lower in CADefirst group and the 1st pass adenoma per colonoscopy (APC) was higher in the CADe-first group.

Based on the clinical performance as documented in the pivotal clinical study, the EndoScreener has a safety and effectiveness profile that is similar to the predicate device.

{5}------------------------------------------------

### Conclusions

The EndoScreener is as safe and effective as the GI Genius. The EndoScreener has the same intended uses and similar indications, technological characteristics, and principles of operation as its predicate device. The minor differences in indications do not alter the intended use of the device and do not affect its safety and effectiveness when used as labeled. In addition, the minor technological differences between the EndoScreener and its predicate device raise no new issues of safety or effectiveness. Performance data demonstrate that the EndoScreener is as safe and effective as GI Genius. Thus, the EndoScreener is substantially equivalent.